CrossAssetDataThe Company File
···
LNTH

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in North Billerica, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.5 billion and a profit of $234 million (its filed statements).

Product business In Vitro & In Vivo Diagnostic Substances North Billerica, MA filings since 2014 9 of 9 filed
Ask the desk about LNTH → Compare LNTH with NEOG → Price chart on TradingView ↗ Full EDGAR file ↗ Watch LNTH →

Sector peers: NEOGIDXXQDELNTLA

6.7/10headline grade
vs its business-model standard
8.6/10past 7.0/10present 4.5/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2835, In Vitro & In Vivo Diagnostic Substances); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.7 out of ten, 9 of 9 metrics filed: past 8.6 out of ten, present 7.0 out of ten, future 4.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.9 out of ten. No warning events in its filings since 2017. 89th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 8.8 out of ten. +21.2% a year over 9 filed years; profitable in 6 of 7. 88th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 7.5 out of ten. Share count shrank 1.1% a year. 32% of cash flow returned. Insiders: 0 sales, 0 purchases. 75th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 7.6 out of ten. ROE 21%: 21¢ of profit per shareholder dollar. Leverage 51%: owes 51¢ per asset dollar. 76th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 8.3 out of ten. top 17% of 17 in its family; net margin 15.2%. 83rd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.1 out of ten. bottom 41% of 15 in its family for leadership; chief executive since 2026. 41st percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.8 out of ten. top 42% of 16 in its family for room to expand. 58th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 3.6 out of ten. bottom 36% of 17 in its family for growth drivers. 36th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.1 out of ten. bottom 31% of 16 in its family for expectations against reality. 31st percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form DEFA14A, 2026-10-02. Filings on record since 2014. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: PYLARIFY 64%, Definity 21%, Techne Lite 6%, Strategic Partnerships and Other 4%, Neuraceq 3%, Other Precision Diagnostics 2%. By geography: United States 95%, Outside the United States 5%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Heino, Mary Anne (Executive Chair and CEO); Blanchfield, Paul (President); Marshall, Robert J. Jr. (CFO and Treasurer); Brown, Kimberly (Chief Accounting Officer); Niedzwiecki, Daniel (Chief Administrative Officer, General Counsel and Corporate Secretary); Morgan, Amanda Michelle (Chief Commercial Officer); Dinkelborg, Ludger (Head of Research and Development); Ber, Gerard (director); Baylor-Henry, Minnie (director); Eastland, Julia Marie (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.